New research indicates that semaglutide, an injectable medication currently marketed as Ozempic for diabetes and Wegovy for weight management, could be produced at a fraction of its current cost, making it accessible to millions in low-income countries. This breakthrough comes at a crucial time, as obesity and diabetes rates continue to rise globally, particularly in regions experiencing shifts towards Western dietary habits.
The Promise of Lower Prices
A recent analysis revealed that semaglutide could be manufactured for approximately $3 (around £2.35) per month, significantly reducing the financial barriers for those in need. This low production cost could facilitate access to the medication across 160 nations, many of which are struggling with high rates of obesity and diabetes. The World Health Organization designated semaglutide as an essential medicine in September 2022, underscoring the global health community’s recognition of its importance in combating these chronic conditions.
Dr Andrew Hill from the University of Liverpool, one of the study’s authors, remarked, “These low prices open the door to worldwide access to an essential medicine.” The research highlights that patents on semaglutide will expire in several countries, including Brazil, China, and India, starting from March 21, 2026, paving the way for generic versions to enter the market.
Expanding Access in Low and Middle-Income Countries
The study identifies over 150 countries where patents for semaglutide have not been filed, primarily across Africa. This represents a significant opportunity, as these regions are home to 69% of individuals with type 2 diabetes and 84% of those living with obesity. Professor François Venter from the University of Witwatersrand emphasised the potential to replicate past successes seen with generic medications for HIV, tuberculosis, and malaria, which have dramatically improved health outcomes in low- and middle-income countries (LMICs).
Dr Nomathemba Chandiwana, chief scientific officer at South Africa’s Desmond Tutu Health Foundation, noted that cost has long been a barrier to access in many LMICs. She expressed optimism that lower prices for semaglutide could significantly impact healthcare delivery in these regions, where approximately 27% of adults meet the criteria for such treatments.
Addressing Underlying Health Challenges
While the potential for affordable semaglutide is promising, experts caution that simply providing access to medication will not resolve the broader structural issues contributing to obesity and diabetes. Factors such as food insecurity, economic disparity, and urbanisation must be addressed through coordinated health policies and strategic procurement planning.
The rising prevalence of obesity is linked to numerous health complications, including heart disease, diabetes, and certain cancers. With 3.7 million deaths attributed to excess weight annually, the urgency for effective interventions has never been greater.
The Future of Semaglutide
Semaglutide was first approved in the United States in 2017 and is currently priced around $200 a month in the US and £120 in the UK, with patents in these regions not set to expire for another five years. However, the study’s findings suggest a shift towards more affordable options could soon be on the horizon, aligning with global health goals for equitable access to essential medicines.
This research builds upon prior investigations, including a 2024 study by Médecins Sans Frontières, which also indicated that diabetes treatments could be manufactured and sold at significantly lower prices.
Why it Matters
The findings surrounding semaglutide’s production costs present a transformative opportunity for global health, potentially bridging the gap in access to critical treatments for diabetes and obesity in underserved populations. As countries grapple with rising rates of these chronic diseases, the implementation of affordable medications could not only enhance individual health outcomes but also alleviate the burden on healthcare systems worldwide, ultimately saving millions of lives. The challenge now lies in ensuring that these medications are integrated responsibly into broader healthcare strategies that address the underlying causes of obesity and diabetes.
